BACKGROUND: Management of MPM is complex and controversial as there is a paucity of good quality evidence. We report the toxicity and outcomes in patients who received trimodality treatment for non-metastatic MPM at our institution. METHODS & MATERIALS: We reviewed the electronic medical records of surgically managed MPM patients at our institution in the last decade. Dosimetric parameters of target volume and organs at risk were documented by the treatment planning workstation. SPSS was used for statistical analysis. RESULTS: Between January 2008 and October 2018, 21 patients underwent surgery for MPM - all but 2 patients underwent extra-pleural pneumonectomy (EPP); epithelioid MPM was the most common histology. All patients, except 2, received neoadjuvant Pemetrexed/platinum doublet chemotherapy. Fourteen patients received adjuvant hemithoracic RT; ten patients were treated with a conformal technique at our institute and dosimetric data was available for analysis. Average time to start RT after surgery was 51 days (range 32-82 days). All patients were treated with a conformal technique using IMRT/VMAT to a dose of 45Gy in 25 fractions. Mean overall RT duration was 35 days (range 30-42 days). Grade I/II Pneumonitis was seen in 4 patients. One patient developed grade III acute lung toxicity unrelated to RT. At a median follow up of 25 months, 8 patients had died, of whom six died due to the disease and two died in the immediate post op period. Two-year DFS and OS were 58% and 73%, respectively. CONCLUSION: In spite of the extensive surgery and complex hemithoracic RT, we demonstrated excellent dosimetry, toxicity profile and favorable outcomes in non-metastatic MPM.
BACKGROUND: Management of MPM is complex and controversial as there is a paucity of good quality evidence. We report the toxicity and outcomes in patients who received trimodality treatment for non-metastatic MPM at our institution. METHODS & MATERIALS: We reviewed the electronic medical records of surgically managed MPM patients at our institution in the last decade. Dosimetric parameters of target volume and organs at risk were documented by the treatment planning workstation. SPSS was used for statistical analysis. RESULTS: Between January 2008 and October 2018, 21 patients underwent surgery for MPM - all but 2 patients underwent extra-pleural pneumonectomy (EPP); epithelioid MPM was the most common histology. All patients, except 2, received neoadjuvant Pemetrexed/platinum doublet chemotherapy. Fourteen patients received adjuvant hemithoracic RT; ten patients were treated with a conformal technique at our institute and dosimetric data was available for analysis. Average time to start RT after surgery was 51 days (range 32-82 days). All patients were treated with a conformal technique using IMRT/VMAT to a dose of 45Gy in 25 fractions. Mean overall RT duration was 35 days (range 30-42 days). Grade I/II Pneumonitis was seen in 4 patients. One patient developed grade III acute lung toxicity unrelated to RT. At a median follow up of 25 months, 8 patients had died, of whom six died due to the disease and two died in the immediate post op period. Two-year DFS and OS were 58% and 73%, respectively. CONCLUSION: In spite of the extensive surgery and complex hemithoracic RT, we demonstrated excellent dosimetry, toxicity profile and favorable outcomes in non-metastatic MPM.
Authors: Andreas Rimner; Marjorie G Zauderer; Daniel R Gomez; Prasad S Adusumilli; Preeti K Parhar; Abraham J Wu; Kaitlin M Woo; Ronglai Shen; Michelle S Ginsberg; Ellen D Yorke; David C Rice; Anne S Tsao; Kenneth E Rosenzweig; Valerie W Rusch; Lee M Krug Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: Daniel R Gomez; David S Hong; Pamela K Allen; James S Welsh; Reza J Mehran; Anne S Tsao; Zhongxing Liao; Stephen D Bilton; Ritsuko Komaki; David C Rice Journal: J Thorac Oncol Date: 2013-02 Impact factor: 15.609
Authors: David C Rice; Craig W Stevens; Arlene M Correa; Ara A Vaporciyan; Anne Tsao; Kenneth M Forster; Garrett L Walsh; Stephen G Swisher; Wayne L Hofstetter; Reza J Mehran; Jack A Roth; Zhongxing Liao; W Roy Smythe Journal: Ann Thorac Surg Date: 2007-11 Impact factor: 4.330
Authors: Christopher Cao; David Tian; John Park; James Allan; Kristopher A Pataky; Tristan D Yan Journal: Lung Cancer Date: 2013-12-06 Impact factor: 5.705
Authors: Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto Journal: Lancet Oncol Date: 2011-06-30 Impact factor: 41.316
Authors: Emanuela Taioli; Andrea S Wolf; Marlene Camacho-Rivera; Andrew Kaufman; Dong-Seok Lee; Daniel Nicastri; Kenneth Rosenzweig; Raja M Flores Journal: PLoS One Date: 2015-12-14 Impact factor: 3.240